Regentis Biomaterials Secures U.S. Patent for GelrinC Liquid Formulation, Advances Clinical Trial
TL;DR
Regentis Biomaterials secures a patent through 2038 for its GelrinC liquid formulation, giving it a competitive edge in the knee cartilage repair market with no current off-the-shelf alternatives.
The patent covers a solvent-free liquid formulation of GelrinC that conforms to cartilage wounds and is cured with UV light to form a temporary elastomeric implant.
This innovation simplifies surgical procedures and improves patient experience, potentially restoring health and enhancing quality of life for thousands needing knee cartilage repair annually.
Regentis has surpassed 50% enrollment in its FDA clinical trial for a cell-free hydrogel that regenerates cartilage through a controlled, synchronous process as it resorbs.
Found this article helpful?
Share it with your network and spread the knowledge!
Regentis Biomaterials Ltd. has received a new U.S. patent covering a liquid, ready-to-use formulation of its lead product GelrinC, along with improved production processes that eliminate organic solvents. The patent, titled "Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof," provides intellectual property protection for the company's cartilage repair technology through 2038.
The liquid formulation of GelrinC is designed to conform precisely to cartilage wounds during surgical procedures before being cured with UV light to form a temporary elastomeric implant. This approach aims to simplify surgical procedures and improve patient experience by offering a more adaptable treatment option. According to the company, this technology addresses a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is currently available.
Regentis reported that it has surpassed 50% enrollment in its pivotal U.S. Food and Drug Administration clinical trial for knee cartilage repair. Executive Chairman Dr. Ehud Geller noted this milestone in connection with the patent announcement, indicating progress toward potential regulatory approval. The company's Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone.
GelrinC is a cell-free, off-the-shelf hydrogel that erodes and resorbs in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The new patent specifically covers the liquid formulation and production methods that eliminate organic solvents, potentially improving manufacturing safety and efficiency. For more information about Regentis Biomaterials, visit https://www.regentis.co.il/.
The patent protection through 2038 provides Regentis with extended commercial exclusivity for its liquid GelrinC formulation, which could be significant as the company advances through clinical trials. This intellectual property protection may enhance the company's valuation and attractiveness to potential partners or investors in the regenerative medicine space. The technology represents an innovation in orthopedic treatments where current options for cartilage repair remain limited.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. The company's initial focus on orthopedic treatments addresses a significant unmet medical need, particularly in knee cartilage repair where existing treatments often involve complex procedures with variable outcomes. The liquid formulation patent represents both a technical advancement and strategic asset as the company progresses toward potential commercialization.
Curated from InvestorBrandNetwork (IBN)
